Leishmania in SLE mimicking an exacerbation

Clinical and Experimental Rheumatology

Volumn 24, Issue 2, 2006, Pages 186-190

  Ossandon, Alejandra ^a   Bompane, Daniela ^a   Alessandri, Cristiano ^a   Marocchi, Elisa ^a   Conti, Fabrizio ^a   Valesini, Guido ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Fever; Pancytopenia; Systemic lupus erythematosus; Visceral leishmaniasis

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B LIPID COMPLEX; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MEGLUMINE ANTIMONATE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STIBOGLUCONATE SODIUM;

ADULT; AMASTIGOTE; ANEMIA; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; COOMBS TEST; DISEASE DURATION; DISEASE EXACERBATION; DRUG DOSE REGIMEN; ECHOGRAPHY; HEPATOMEGALY; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; IMMUNOFLUORESCENCE TEST; ITALY; KIDNEY BIOPSY; KIDNEY DYSFUNCTION; LABORATORY TEST; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; LEUKOPENIA; MALE; PATIENT REFERRAL; PRIORITY JOURNAL; PROLIFERATIVE GLOMERULONEPHRITIS; PROTEINURIA; REMISSION; SEROLOGY; SPLENOMEGALY; SYSTEMIC LUPUS ERYTHEMATOSUS; VISCERAL LEISHMANIASIS;

ADULT; AMPHOTERICIN B; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIPROTOZOAL AGENTS; BONE MARROW; DIAGNOSIS, DIFFERENTIAL; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; RECURRENCE;

EID: 33744806072     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. FERNANDEZ-GUERRERO ML, AGUADO JM, BUZON L et al.: Visceral leishmaniasis in immunocompromised hosts. Am J Med 1987; 83: 1098-102.
2. WALLIS PJ, CLARK CJ: Visceral leishmaniasis complicating systemic lupus erythematosus. Ann Rheum Dis 1983; 42: 201-2.
3. ALTOZANO JG, LÓPEZ-GÓMEZ JM, ROBLES R, MUIÑO A, ROMERO J, VALDERRÁBANO F: Leishmaniasis visceral en el lupus eritématoso sistemico. Med Clin (Barc) 1987; 88:417-8.
4. BRAUN J, SIEPER J, SCHULTE KL, THIEL E, JANITSCHKE K: Visceral leishmaniasis mimicking a flare of systemic lupus erythematosus. Clin Rheumatol 1991; 10: 445-8.
5. CAPELL S, ARANDA M, COLOMÉ A, LÓPEZ R, PUJOL R: Visceral leishmaniasis. Ann Rheum Dis 1993; 52: 551.
6. GRANEL B, SERRATRICE J, SWAIDER L et al.: Crossing of antinuclear antibodies and antileishmania antibodies. Lupus 2000; 9: 548-50.
7. GAETA GB, GRADONI L, GRAMICCIA M et al.: Visceral leishmaniasis in Italy. Its epidemiology, clinical picture and therapy. Recenti Prog Med 1994; 85: 340-7.
8. DESJEUX P: Leishmaniasis: public health aspects and control. Clin Dermatol 1996; 14: 417-23.
9. DAVIDSON RN: Visceral leishmaniasis in clinical practice. J Infect 1999; 39: 112-6.
10. BADARO R, JONES TC, CARVALHO EM et al.: New perspectives on a sub-clinical form of visceral leishmaniasis. J Infect Dis 1986: 154: 1003-11.
11. BAILY GG, NANDY A: Visceral leishmaniasis: more prevalent and more problematic. J Infect 1994; 29: 241-7.
12. PEARSON RD, DE QUEIROZ SOUSA A: Clinical spectrum of leishmaniasis. Clin Infect Dis 1996; 22: 1-13.
13. ALEXANDER J, SATOSKAR AR, RUSSELL DG: Leishmania species: models of intracellular parasitism. Journal of cell science 1996; 112: 2993-3002.
14. MIESCHER PA, BELEHU A: Leishmaniasis: hematologic aspects. Semin Hematol 1982; 19: 93-9.
15. ORTA C, AYATS R, PORTUS M, CADAFALCH J: Visceral leishmaniasis mimicking histiocytic marrow reticulosis. Sangre 1986; 31: 90-5.
16. CASATO M, DE ROSA FG, PUCILLO LP et al.: Mixed cryoglobulinemia secondary to visceral leishmaniasis 1999. Arthr Rheum 1999; 42: 2007-11.
17. GALVAO-CASTRO B, SA FERREIRA JA, MARZOCHI KF, MARZOCHI MC, COUTINHO SG, LAMBERT PH: Polyclonal B cell activation, circulating immune complexes and autoimmunity in human american visceral leishmaniasis. Clin Exp Immunol 1984; 56: 58-66.
18. ARGOV S, JAFFE CL, KRUPP M, SLOR H, SHOENFIELD Y: Autoantibodies production by patients infected with leishmania. Clin Exp Immunol 1989; 76: 561-8.
19. DISDIER P, DELAGE Y, VAISSE B, AILLAUD MF, FENASSE R, BERNARD PM: Circulating anticoagulant during visceral mediterranean leishmaniasis. Presse Med 1990; 19: 922.
20. CARVALHO EM, ANDREWS BS, MARTINELLI R, DUTRA M, ROCHA M: Circulating immune complexes and rheumatoid factor in schistosomiasis and visceral leishmaniasis. Am J Trop Med Hyg 1983; 32: 61-8.
21. ABU-SHAKRA M, BUSKILA D, SHOENFELD Y: Molecular mimicry between host and pathogen: examples from parasites and implication. Immunol Lett 1999; 67: 147-52.
22. LIEW FY, O'DONNEL CA: Immunology of leishmaniasis. Adv Parasitol 1993; 32: 161-259.
23. SATOSKAR A, BLUETHMANN H, ALEXANDER J: Disruption of the murine interleukin-4 gene inhibits disease progression during leishmania mexicana infection but does not increase control of leishmania donovani infection. Infec Immun 1995; 63: 4894-9.
24. ALEXANDER J, CARTER KC, AL-FASI N, SATOSKAR A, BROMBACHER F: Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis. Eur J Immunol 2000; 30: 2935-43.
25. AKAHOSHI M, NAKASHIMA H, TANAKA Y et al.: Th1/Th2 balance of peripheral T helper cells in systemic lupus erythematosus. Arthritis Rheum 1999; 42: 1644-8.
26. DUTRA M, MARTINELLI R, DE CARVALHO EM, RODRIGUES LE, BRITO E, ROCHA H: Renal involvement in visceral leishmaniasis. Am J Kidney Dis 1985; 6:22-7.
27. WEISINGER JR, PINTO A, VELAZQUEZ GA et al.: Clinical and histological kidney involvement in human Kala-azar. Am J Trop Med Hyg 1978; 27: 357-9.
28. SCATENA P, MESSINA F, GORI S, RUOCCO L et al.: Visceral leishmaniasis in a patient treated for polyarteritis nodosa. Clin Exp Rheumatol 2003; 2: S121-3.
29. ZANALDI H, ROSENTHAL E, MARTY P, CHICHMANIAN RM, PESCE A, CASSUTO JP: Visceral leishmaniasis associated with Wegener disease. Use of lipid complex amphotericin B and liposomal amphotericin B. Presse Med 1999; 28: 959-61.
30. MEYERHOFF A: U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis 1999; 28: 42-8.